Eli Lilly Halts Phase III Trial of Verzenio in Prostate Cancer

The CYCLONE-2 study aimed to evaluate the efficacy of Verzenio in combination with Zytiga (abiraterone) but did not meet its primary endpoint. This development underscores the challenges pharmaceutical companies face in finding effective treatments for mCRPC, a form of the disease that progresses despite hormonal therapy aimed at reducing testosterone levels.

Eli Lilly’s commitment to combatting various forms of cancer remains undeterred, as evidenced by its recent $1.4 billion acquisition of Point Biopharma. However, the acquisition’s lead drug has faced setbacks, particularly when compared to Novartis’ Pluvicto. Similarly, Johnson & Johnson has entered the fray with a $2 billion investment in Ambrx Biopharma’s antibody-drug conjugates, highlighting the competitive landscape of prostate cancer treatment research.

This announcement marks the second recent setback for Verzenio, following its failure to meet overall survival goals in an advanced breast cancer trial and a previous Phase II prostate cancer study as a monotherapy. Despite these challenges, Verzenio has excelled in the breast cancer market, generating $3.86 billion in full-year sales for Lilly in 2023, marking a 56% increase from the previous year.

Eli Lilly also noted that another Phase III trial is ongoing to assess Verzenio’s effectiveness in hormone-sensitive prostate cancer, reflecting the company’s continued exploration of the drug’s potential across different cancer types. Additionally, the company disclosed the removal of a Phase I RET inhibitor from its development pipeline, signaling a strategic refocusing on its most promising therapeutic candidates.

The failure of the CYCLONE-2 trial in mCRPC represents a significant disappointment for Eli Lilly, especially considering Verzenio’s robust performance in the breast cancer domain. The drug, which received its first-in-class FDA approval in 2021 for certain patients with HR-positive, HER2-negative early breast cancer post-surgery, had previously shown promise in early trial phases. Unfortunately, the anticipated benefits did not extend to a broader patient population in the subsequent Phase III study, despite maintaining a consistent safety profile.

As the pharmaceutical industry continues to navigate the complex landscape of cancer treatment, Eli Lilly’s experiences underscore the unpredictability of drug development and the importance of ongoing research to address unmet medical needs.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services